Samples

Revenue segments as reported by the company.

Test revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Change in fair value of contingent consideration

Asset impairment

Restructuring

Gain on sale of RUO kit assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Invitae

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Invitae reports strong Q4 earnings, eyes growth amid challenges

Invitae's Q4 2022 performance showcased revenue growth, improved margins, and reduced cash burn, positioning the company for sustainable growth.
Strategic investments in key growth areas and a focus on customer experience and profitability underpin Invitae's vision for the future.
Addressing supply chain challenges while seizing opportunities for expansion and innovation will be critical for Invitae's continued success.

Invitae (NVTA) reports robust Q1 earnings and advances in PCM technology

Invitae's Q1 2023 earnings call highlighted strong financial performance, operational strengths, and strategic advancements in PCM technology.
The company's focus on growth, margin expansion, and debt management underscores a path towards sustainable profitability.
While facing challenges in reimbursement dynamics and competitive landscape, Invitae remains poised to capitalize on growth opportunities.

Invitae reports Q2 revenue growth, adjusts guidance amid challenges

Invitae shows progress towards profitability with improved margins and reduced cash burn.
Challenges in hereditary cancer revenue and PGX exit impact revenue guidance.
Focus on expanding customer base, improving reimbursement, and reducing cash burn.
Continuous investment in products for future growth and competitiveness.

Invitae reports robust Q3 earnings, addresses financial concerns proactively

Invitae's Q3 2023 performance was strong, with revenue growth and margin expansion. The company faces challenges in capital structure and insurance payments but is actively addressing them. Opportunities lie in revenue growth, operational improvements, and expanding genetic testing services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people. Specializing in genetic diagnostics for hereditary disorders, Invitae aggregates the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today.

SAN FRANCISCO, Oct. 26, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2021 financial results on Monday, November 8, 2021, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m.

Invitae to Announce Third Quarter 2021 Financial Results on Monday, November 8, 2021

Coinbase

Teladoc

All eyes will be watching these ARK Invest holdings to see if they're working out as hoped.

3 Cathie Wood Stocks to Watch This Earnings Season

Bears are underestimating Invitae's health information platform. Stock stuck in a trading range of $27-32, falling after the Ciitizen acquisition.

Why Invitae's Genomic Solution Will Drive Shares Higher

SAN FRANCISCO, Oct. 22, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), University College London (UCL), and the Francis Crick Institute today announced new data from their TRACERx lung cancer research collaboration funded by Cancer Research UK and sponsored by UCL. The data, presented by Professor Charles Swanton of UCL and the Francis Crick Institute at the International Society of Liquid Biopsy (ISLB) Congress, further validate the value of liquid biopsy as a less invasive and more comprehensive approach to guiding personalized cancer treatment in the absence of detectable disease by clinical imaging.

Invitae, UCL and the Francis Crick Institute Announce New Data From TRACERx Research Collaboration at the 2021 International Society of Liquid Biopsy Congress

BOSTON--(BUSINESS WIRE)-- #breastcancer--Outcomes4Me Inc., developer of a leading free mobile app and platform to navigate cancer treatment and care, today announced that it has partnered with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to expand education and access to genetic testing to breast cancer patients and survivors. The collaboration leverages the strengths of Invitae, which supplies clinical grade genetic testing, and Outcomes4Me's 360-degree, validated and evidence-based c

Outcomes4Me Partners with Invitae to Offer Genetic Testing to Breast Cancer Patients

Renalytix AI plc

SoFi Technologies

Analyst estimates suggest these stocks can deliver eye-popping gains once the rest of the stock market views them in the same light.

3 Growth Stocks Wall Street Thinks Could Rise 50% or More

908 Devices

Signify Health

ARK Invest's founder and CEO isn't shy about averaging down on her favorite growth stocks.

3 Sinking Stocks Cathie Wood Keeps Buying Anyway

SAN FRANCISCO, Sept. 25, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today presented research demonstrating that genetic findings informed clinical management changes that led to improved seizure control and outcomes in the majority of epilepsy patients with actionable findings.

New Study Highlights the Value of Genetic Testing to Guide Clinical Management and Improve Outcomes for Epilepsy Patients

ARK Innovation ETF

Personalis Inc

The CEO of ARK Invest is averaging down on these compelling life-science stocks.

Cathie Wood Goes Bargain Shopping: 3 Sinking Stocks She Keeps Buying

Invitae Corporation (NVTA) Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)

CRISPR Therapeutics

All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.

Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought

On Tuesday, Invitae Corp (NYSE:NVTA) shares edged slightly lower after announcing the purchase of health tech company Ciitizen in a cash and stock deal worth $325 million. The company will pay $125 million in cash and issue 7.07 million shares of common stock.

As Invitae pays $325 million to buy Ciitizen, should you invest in NVTA shares?

Invitae Corp (NYSE: NVTA) has agreed to acquire consumer health technology company Ciitizen for $325 million in a bid to make it easier for patients to collect their genomic and clinical information. Ciitizen, backed by several investors, including a16z, Section 32, and Verily, is building a digital platform that will enable patients to collect, store, and share their medical records.

Invitae Strengthens Health Data Platform With Ciitizen Acquisition

SAN FRANCISCO, Sept. 7, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Ciitizen, a patient-centric consumer health tech company.

Invitae to Acquire Ciitizen to Strengthen its Patient-Consented Health Data Platform to Improve Personal Outcomes and Global Research

SAN FRANCISCO, Sept. 1, 2021 /PRNewswire/ --  Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021, at 12:30pm Eastern Time.

Invitae to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

Bristol-Myers

Cameco

Equity Commonwealth

MasTec

Muhlenkamp & Co. Inc., the investment firm founded by Ronald Muhlenkamp (Trades, Portfolio), released its portfolio for the second quarter earlier this month.

Ron Muhlenkamp's Firm Goes 1 for 1 in 2nd Quarter

ARK Fintech Innovation ETF

ARK Web x.0 ETF

Palantir Technologies

Quantum-Si

StoneCo

Zillow

Cathie Wood continues to pick up stocks through her ARK Invest ETFs and we're taking a look at some of their top investments for Tuesday. The post Cathie Wood Stocks: What Names Is ARK Invest CEO Buying Now?

Cathie Wood Stocks: What Names Is ARK Invest CEO Buying Now?

SAN FRANCISCO, Aug. 9, 2021 /PRNewswire/ --  Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will participate in a fireside chat at the UBS Genomics 2.0 and MedTech Innovations Summit on Wednesday, August 11, 2021 at 11:00 a.m. PT and Sean George, chief executive officer of Invitae, will participate in the NGS Technologies panel presentation at 1:00 p.m.

Invitae to Present at the UBS Genomics 2.0 and MedTech Innovations Summit

Exact Sciences

EXACT Sciences Corporation (NASDAQ: EXAS) reportedly approached Invitae Corp (NYSE: NVTA) for a potential merger. These are the details.

Report: Exact Sciences (EXAS) Approached Invitae (NVTA) For Merger Offer

This genetic testing innovator slumped along with other genomics stocks last month.

Why Did Invitae Stock Fall 17% in July?

Accelerating growth is giving investors more confidence in the genetic testing company's long-term prospects.

Why Invitae Stock Is Climbing Today

Invitae Corporation (NYSE: NVTA), after the close of the market on Tuesday, reported its second-quarter revenues of $116.3 million, +152% Y/Y, exceeding the consensus Wall Street estimate of $108.3 million. Revenues from testing totaled $111.5 million, a sharp increase from $45.1 million in Q2 2020.

Invitae Stock Jumps As Higher Test Volume More Than Doubles Q2 Topline, Raises FY21 Sales Outlook

The stock price of Invitae Corp (NYSE: NVTA) increased by over 8% pre-market. This is why it happened.

NVTA Stock Price Increases Over 8% Pre-Market: Why It Happened

Invitae Corporation's (NVTA) CEO Sean George on Q2 2021 Results - Earnings Call Transcript

Invitae (NVTA) delivered earnings and revenue surprises of -30.77% and 6.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

News for Invitae Stock (NVTA)